"We are building a leading lentiviral-based cell and gene therapy company using our versatile dual technology platform and in-house manufacturing capabilities to advance development of potentially transformative therapies for patients and families seeking relief from devastating genetic diseases."
Matthew Gantz, President and Chief Executive Officer
Courtesy of debra—The Dystrophic Epidermolysis Bullosa Research Association of America and the Oliveira family. Used with permission.
Courtesy of the Pratt family. Used with permission